文献速递癫痫

癫痫患者中仿制与原研拉莫三嗪的生物等效性:EQUIGEN随机临床试验

Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2017-01-01

EQUIGEN单剂量交叉随机对照试验在5个美国学术癫痫中心纳入50例正在服用其他抗癫痫药且未用拉莫三嗪的成人癫痫患者,比较1种原研药与2种市售仿制拉莫三嗪即释片的生物等效性。结果显示三种产品Cmax与AUC的90%CI均在80%–125%等效限内,判定为生物等效。

要点

  • 在成人癫痫患者中,1种原研与2种仿制拉莫三嗪即释片单次25 mg给药后生物等效。
  • Cmax比值90%CI为92.6%–110.4%,AUC0-96比值90%CI为96.9%–101.9%,均在等效限内。
  • 重复给药测试显示三产品个体内变异无显著差异,支持仿制替换。

核心结论

  • 所研究的1种原研与2种市售仿制拉莫三嗪即释片在服用其他抗癫痫药的癫痫患者中经单剂量药代动力学测试判定为生物等效。

研究设计与样本

  • EQUIGEN为交叉、前瞻性、序列随机、重复药代动力学研究,在美国5个学术癫痫中心开展。
  • 2013年7月18日至2015年1月19日纳入50例≥18岁、正在服用伴随抗癫痫药且当前未用拉莫三嗪的癫痫成人,49例纳入意向治疗分析。
  • 每例随机分配至3种等效序列之一,每序列含6个研究期,每期开始单次口服25 mg拉莫三嗪即释片,原研药与2种差异最大的仿制药各研究2次,受试者与研究人员对具体仿制产品设盲。

主要发现

  • 49例中28例(57%)为男性、21例(43%)为女性,42例(86%)自报为白人,平均(SD)年龄46(16)岁。
  • 49例中49例(98%)接受全部3种产品并完成至少3次药代动力学评估,46例(92%)完成全部6次评估。
  • 三产品Cmax比值90%CI最低与最高限为92.6%与110.4%,AUC0-96为96.9%与101.9%,均在80%–125%等效限内,判定生物等效。
  • 重复测试显示三产品个体内变异无显著差异(对数转换变量似然比χ22:AUC0-96 2.58、Cmax 0.64、AUC0-∞ 4.05;P≥.13)。
  • 按标度平均生物等效与个体生物等效标准三产品亦生物等效,无受试者×制剂交互作用(Cmax 0.00、AUC0-96 0.54、AUC0-∞ 0.36;P≥.76)。

关键数值与推荐

  • 主要结局为产品间生物等效性,以Cmax和AUC比较,若两产品比值90%CI落在80%–125%等效限内则判定平均生物等效。

临床怎么用

  • 该研究为癫痫患者中差异较大的拉莫三嗪仿制产品可生物等效提供了单剂量药代动力学证据,可供临床讨论仿制替换时参考。
  • 解读时需注意本研究为单剂量25 mg即释片设计,未评估多剂量稳态及临床发作结局。

局限性

  • 为单剂量药代动力学研究,每期仅给25 mg即释拉莫三嗪,未评估稳态多剂量。
  • 样本以自报白人为主(42/49,86%),且为服用伴随抗癫痫药的成人,外推需谨慎。
  • 未报告临床癫痫发作或不良反应结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Switching between generic antiepileptic drugs is a highly debated issue that affects both clinical care and overall health care costs. OBJECTIVE: To evaluate the single-dose pharmacokinetic bioequivalence of 3 (1 branded and 2 generic drugs) on-market, immediate-release lamotrigine drug products. DESIGN, SETTING, AND PARTICIPANTS: The Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy (EQUIGEN) single-dose study is a crossover, prospective, sequence-randomized, replicate pharmacokinetic study conducted at 5 US academic epilepsy centers. Fifty adults (≥18 years) with epilepsy who were taking concomitant antiepileptic drugs and not currently receiving lamotrigine were enrolled between July 18, 2013, and January 19, 2015. Every participant was randomly assigned to 1 of 3 equivalent sequences, each comprising 6 study periods, during which they had blood draws before and after medication administration. Forty-nine participants were included in intention-to-treat analyses. INTERVENTIONS: Participants received a single 25-mg dose of immediate-release lamotrigine at the start of each period, with the branded and the 2 most disparate generic products each studied twice. Lamotrigine was selected as the antiepileptic drug of interest because of its wide use, publications indicating problems with generic switches, and complaints to the US Food and Drug Administration regarding generic products. Both participants and study personnel were blinded to the specific generic products selected. MAIN OUTCOMES AND MEASURES: The primary outcome was bioequivalence between products. Maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) were compared, and average bioequivalence (ABE) was established if the 90% CIs of the ratios of the 2 products were within equivalence limits (80%-125%). RESULTS: Of the 50 randomized participants, 49 (98%) received all 3 lamotrigine products and completed at least 3 pharmacokinetic assessments and 46 (92%) completed all 6 pharmacokinetic assessments. Among the 49 participants, 28 (57%) were men and 21 (43%) were women, 42 (86%) self-identified as white, and 46 (16) years was the mean (SD) age. The 3 drug products were considered bioequivalent because the 90% CIs were within equivalence limits (lowest and highest CI limits for Cmax, 92.6% and 110.4%; for AUC0-96, 96.9% and 101.9%). Replicate testing demonstrated no significant differences in within-subject variability across the 3 products (likelihood ratios, χ22 for log-transformed variables: AUC0-96, 2.58; Cmax, 0.64; and AUC0-∞, 4.05; P ≥ .13) and that the 3 products were also bioequivalent according to scaled ABE and individual bioequivalence criteria with no subject × formulation interaction (Cmax, 0.00; AUC0-96, 0.54; and AUC0-∞, 0.36; P ≥ .76). CONCLUSIONS AND RELEVANCE: This study provides evidence that the disparate lamotrigine products studied are bioequivalent when tested in people with epilepsy taking concomitant antiepileptic drugs. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01733394.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Berg M, Welty TE, Gidal BE, et al. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. JAMA Neurol. 2017. PMID: 28654954. doi:10.1001/jamaneurol.2017.0497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。